BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamel MM, Saad MF, Mahmoud AA, Edries AA, Abdel-moneim AS. Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma. Microbial Pathogenesis 2014;77:31-5. [DOI: 10.1016/j.micpath.2014.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Xu J, Liu X. PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition. Journal of Hepatology 2015;63:1040-1. [DOI: 10.1016/j.jhep.2015.04.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
2 Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47. [PMID: 28852419 DOI: 10.1186/s13027-017-0153-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
3 Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P, Lou J. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumour Biol 2017;39:1010428317705763. [PMID: 28621228 DOI: 10.1177/1010428317705763] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hauser S, Kaminski A, Syring I, Holdenrieder S, Dieckmann KP, Muller SC, Ellinger J. Evaluation of Serum Biomarkers (FGF-2, HGF, MIF and PTN) in Patients With Testicular Germ Cell Cancer. In Vivo 2019;33:1935-40. [PMID: 31662522 DOI: 10.21873/invivo.11688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]